Bruce Weed Jr’s Post

🚀 Exciting developments in oncology research! PRMT5 is emerging as a promising target for cancer treatment. This protein plays a crucial role in gene regulation and has been linked to tumor growth and progression. Targeting PRMT5 could lead to novel therapies that enhance treatment efficacy for various cancers. As the field of epigenetics evolves, understanding PRMT5’s mechanisms opens new avenues for patient-centric treatments. Let’s keep pushing the boundaries of science to improve patient outcomes! 💡 #Oncology #PRMT5 #CancerResearch #Innovation https://lnkd.in/gjAB-pyf

A step towards clinic-ready patient-derived organoids . A recent study provides critical insights into the reliability and robustness of patient-derived organoids as a clinical model of pancreatic cancer. The findings reveal that organoids' gene expression and drug responses are not affected by the brand of extracellular matrix used in the cell culture. However, one commercial product did increase the growth rate of pancreatic tumor organoids, making it particularly well-suited for the fast pace of pancreatic cancer treatment protocols. #ScienceDailynews #InnovativeResearch #NextGenScience #ExploringFrontiers

Veracyte, Inc. #Prostate #Decipher Prostate Genomic Classifier #NCCN Guidelines --Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines --The new NCCN Guidelines classify the Decipher Prostate test as Level 1B according to the “Simon Criteria,” which are published criteria for assigning a level of evidence for clinical biomarkers based on the quality and quantity of evidence available. NCCN summarizes the treatment implications for patients based on their Decipher score and the published evidence from analyses of multiple randomized, phase 3 clinical trials. https://lnkd.in/gV-BvR4P

New Perspective from Karolinska Institutet! High-throughput molecular assays for inclusion in personalised oncology trials – State-of-the-art and beyond. 🔹In the last decades, the development of high-throughput molecular assays has revolutionised cancer diagnostics, paving the way for the concept of personalised cancer medicine.  🔹In this review, strengths and limitations of various state-of-the-art sequencing technologies, including gene panel sequencing (DNA and RNA), whole-exome/whole-genome sequencing and whole-transcriptome sequencing, are explored. 🔹We propose a set of recommendations for consideration when planning a new precision cancer medicine trial. #personalisedcancermedicine #Precisionmedicine #Precisioncancermedicine

📃Scientific paper: Novel gene signature for predicting biochemical recurrence-free survival of prostate cancer and PRAME modulates prostate cancer progression Abstract: Biochemical recurrence (BCR) is considered as an early sign of prostate cancer (PCa) progression after initial treatment, such as radical prostatectomy and radiotherapy; hence, it is important to stratify patients at risk of BCR. In this study, we established a robust 8-gene signature (APOF, Clorf64, RPE65, SEMG1, ARHGDIG, COMP, MKI67 and PRAME) based on the PCa transcriptome profiles in the Cancer Genome Atlas (TCGA) for predicting BCR-free survival of PCa, which was further validated in the MSK-IMPACT Clinical Sequencing Cohort (MSKCC) PCa cohort. Moreover, we found that one risk-related gene (PRAME) was upregulated in tumor samples, particularly in high-risk group was well as in patients metastatic tumor and was correlated with chemotherapeutic drug response. In vitro experiments showed that knocking down PRAME reduced the proliferation, migration, and invasion of PCa cells. Therefore, our study established a new 8-gene signature that could accurately predict the BCR risk of PCa. Inhibition of PRAME attenuated the proliferation, invasion, and migration of PCa cells. These findings provide a novel tool for stratifying high-risk PCa patient and shed light on the mechanism of PCa progression. Continued on ES/IODE ➡️ https://etcse.fr/7r4O ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

One of the most important objectives of precision oncology is to provide highly-personalized treatments for patients. This can be achieved by various biomarkers, especially imaging parameters and gene expression signatures are commonly used. Yet combination approaches are sparse for a variety of reasons. This recent study aimed to independently validate the prognostic value of tumor asphericity measured on preoperative PET scans, and its association with published gene expression signatures in non-small cell lung cancer patients. Their findings suggest that this combination could help improve risk stratification in a group of patients that have an urgent need for a more personalized treatment options. #PrecisionOncology #Cancer #PrecisionMedicine

Here, Justin Kline, MD, University of Chicago, discussed a novel CD5 gene expression signature (CD5sig) that is a useful biomarker to identify #DLBCL subtypes vulnerable to #BTK inhibitor therapies. Learn more: https://lnkd.in/eUkC5Sad #Oncologist #Oncology #OncologyNews #DiffuseLargeBCellLymphoma

The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer:-

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes out on Nature Communications https://lnkd.in/dnrFjr4j Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase🧬 that is overexpressed in castration-resistant #ProstateCancer (CRPC) and plays a crucial role in disease progression and resistance to hormonal therapies This study investigates the lineage-specific roles and differential activities of EZH2 in both prostate adenocarcinoma and neuroendocrine prostate cancer (NEPC) subtypes. ➡️Findings reveal that EZH2 modulates bivalent genes, promoting NEPC-associated transcriptional drivers like ASCL1 and neuronal gene programs in NEPC, while its inhibition leads to differentiation in NEPC. Varadha Balaji Venkadakrishnan Nicole Traphagen Ho Navin Mahadevan Loredana Puca Sheng-Yu Ku Martin Bakht Zach Herbert Michael Tolstorukov David Barbie David Rickman Myles Brown Himisha Beltran

First, our pan-cancer epigenomic analysis revealed multiple primate-specific #ERV families that are enriched within tumor-specific accessible chromatin across all 21 solid tumor types profiled by TCGA. Second, our work shows that ERV-derived enhancers link oncogenic #AP1/MAPK signaling to pathological transcriptional rewiring in colorectal cancer. Components of the #MAPK pathway are frequently mutated in cancers, leading to oncogenic hyperactivation of MAPK signaling which promotes pathological gene expression and tumor cell proliferation. Last, we discovered that #LTR10 elements are frequently affected by tandem repeat expansions that could influence their regulatory activity. Although all LTR10 insertions are fixed in the human population, they contain internal tandem repeats that show high levels of length polymorphism associated with repeat instability, consistent with a recent report of variable-length SVA elements which also contain internal tandem repeats. #ScienceAdvances 17 Jul 2024